Wegovy and Zepbound Savings Cards: How Much You’ll Actually Pay in 2026
With commercial insurance, the Wegovy Savings Card drops your cost to as little as $25 a month, capped at $100 in monthly savings. The Zepbound Savings Card can bring the Zepbound single-dose pen to $25 for a 3-month supply. Neither works with Medicare or Medicaid under the standard program — though eligible Medicare patients can now get Wegovy for $50 a month through a separate bridge program that started July 1, 2026. Without insurance, expect $149–$399 a month for Wegovy depending on dose and form, or $299 a month for Zepbound. Below is exactly who qualifies for each price.
How Much Does the Wegovy Savings Card Save You?
Novo Nordisk calls it a “savings offer” rather than a coupon, but it works the same way: enroll once, take the offer to your pharmacist, and it applies automatically alongside your insurance.
With commercial insurance, eligible patients pay as little as $25 a month, subject to a maximum savings of $100 a month. That means your actual price depends on your plan’s copay — if your copay is higher than $125, the card won’t get you all the way to $25, it just knocks up to $100 off whatever your plan charges.
Who qualifies: you need commercial (private) insurance and a valid Wegovy prescription, and you must be a U.S. resident 18 or older (or a parent/guardian enrolling an adolescent). You are not eligible if you’re enrolled in any government insurance program — with one important exception: the Federal Employees Health Benefits (FEHB) Program, ACA marketplace (Health Exchange) plans, and state employee health plans are not treated as government programs for this offer. If you have one of those three, you still qualify for the commercial-insurance price.
Enrollment takes about three minutes at NovoCare.com, or you can text SAVE to 83757 to get the offer sent to your phone. It activates at the pharmacy counter when your pharmacist runs it alongside your insurance.
How Much Does the Zepbound Savings Card Save You?
Eli Lilly splits the Zepbound Savings Program into two tiers, depending on whether your commercial plan actually covers Zepbound.
If your commercial insurance covers Zepbound: the Zepbound single-dose Pen starts at $25 — and that price covers up to a 3-month prescription, not just one month. The 2.5 mg starting dose is not an approved maintenance dose, so this figure applies to the starting phase of treatment.
If your commercial insurance doesn’t cover Zepbound: the KwikPen for single-patient use, or the single-dose vial, starts at $299 for a 1-month prescription — a flat self-pay-style rate that doesn’t depend on your specific copay.
Who qualifies: you must be 18 or older and a U.S. or Puerto Rico resident, and not enrolled in Medicare, Medicaid, TRICARE, VA, or another government program. The current program terms run through December 31, 2026.
What If You Don’t Have Insurance?
Both manufacturers sell directly to self-pay patients through their own pharmacy channels — NovoCare Pharmacy for Wegovy, LillyDirect for Zepbound — separate from the insurance-based savings cards above.
Wegovy, self-pay through NovoCare Pharmacy:
The Wegovy pill starts at $149 a month for the 1.5 mg or 4 mg dose (this pricing is scheduled to update after August 31, 2026). The Wegovy pen starts at $199 a month for your first two fills as a new patient — a limited-time offer through December 31, 2026 — then moves to $349 a month for ongoing fills. The Wegovy HD pen (7.2 mg) starts at $399 a month for new patients.
Zepbound, self-pay through LillyDirect:
The KwikPen or single-dose vial runs $299 a month for a 1-month supply — the same rate as the “insurance doesn’t cover it” tier above, since both paths route around your pharmacy benefit entirely.
Does Medicare Cover Wegovy or Zepbound?
Wegovy: starting July 1, 2026, eligible Medicare patients can pay $50 a month for Wegovy through the new Medicare GLP-1 Bridge program, for adults prescribed Wegovy for a covered, FDA-approved indication. Eligibility is set by the Centers for Medicare and Medicaid Services (CMS) — this is not a guarantee of coverage, and you should confirm your own eligibility with your plan.
Zepbound: Medicare coverage depends on why it’s prescribed. The FDA-approved indications that can support coverage are obesity, overweight with a weight-related medical condition, or moderate-to-severe obstructive sleep apnea with obesity. There’s no single published Medicare price the way there is for Wegovy’s bridge program — coverage and cost vary by your specific plan and diagnosis.
Neither manufacturer’s standard savings card works with Medicare. If you’re on Medicare, or on Medicaid, TRICARE, or VA coverage, the fastest way to find your real number is our GLP-1 insurance coverage checker — it walks through what’s typical for each plan type in under a minute.
Wegovy vs. Zepbound Savings Card, Side by Side
*Subject to eligibility and terms set by Novo Nordisk and Eli Lilly. †Not a guarantee of coverage; eligibility set by CMS.